Rezdiffra (Resmetirom) Adolescent (12 to 17) Developmental Impact

What Is Resmetirom and Why Does It Matter for Adolescents?

Resmetirom is the first drug approved by the FDA for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (F2, F3) in adults. Its mechanism centers on selective agonism of thyroid receptor-beta, the isoform that governs hepatic lipid metabolism without the cardiac and bone effects of thyroid receptor-alpha. That selectivity works reasonably well in adults. In adolescents aged 12 to 17, the picture is more complicated because TR-β is not exclusively a hepatic receptor during development.

The TR-β Receptor in Adolescent Biology

Thyroid hormone signaling through both TR-α and TR-β regulates longitudinal bone growth, GH/IGF-1 axis maturation, and pubertal progression [1]. Animal studies show that thyroid hormone excess during growth-plate-active periods accelerates epiphyseal fusion and reduces final standing height [2]. Resmetirom's selectivity for TR-β over TR-α reduces but does not eliminate this concern, because TR-β is expressed in chondrocytes and osteoblasts in developing bone [3].

MASLD and MASH Prevalence in U.S. Teenagers

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 10 to 13% of U.S. Adolescents, with MASH (the inflammatory, fibrotic form) present in roughly 3 to 5% of obese adolescent cohorts [4]. These numbers are not trivial. Clinicians treating adolescent obesity-related liver disease will eventually face the question of whether resmetirom has any role in this population, which makes understanding its developmental impact a practical concern today, not a distant theoretical one.

FDA Approval Status and Pediatric Data Gap

The FDA granted resmetirom approval on March 14, 2024, specifically for adults with noncirrhotic MASH and liver fibrosis stages F2 or F3 [5]. The approval was based primarily on the MAESTRO-NASH trial (N=966), which enrolled adults aged 18 and older. No participant in that trial was under 18 [6].

What MAESTRO-NASH Did and Did Not Show

In MAESTRO-NASH, resmetirom 100 mg produced MASH resolution without worsening fibrosis in 25.9% of patients vs. 14.2% placebo (P<0.001), and fibrosis improvement by at least one stage in 24.2% vs. 14.2% placebo (P<0.001) at 52 weeks [6]. Those are clinically meaningful adult outcomes. What MAESTRO-NASH cannot tell us is whether similar efficacy would exist in an adolescent liver still undergoing structural and metabolic maturation, or whether the safety profile would hold in a body with active epiphyseal plates and ongoing hypothalamic-pituitary-gonadal axis development.

Pediatric Study Requirements

Under the Pediatric Research Equity Act (PREA), the FDA may require sponsors to conduct pediatric studies for new drugs that could be used in children [7]. As of July 2025, no completed pediatric efficacy or safety trial for resmetirom in the 12 to 17 age range has been published or registered as complete on ClinicalTrials.gov. The FDA's Pediatric Study Plans and any issued Written Requests or Deferrals are not yet publicly available in the accessdata.fda.gov drug label for resmetirom [5].

Thyroid Receptor-Beta Agonism During Puberty: Specific Risks

Puberty in both sexes involves a surge in GH pulsatility, rising IGF-1 concentrations, and sex-steroid-driven acceleration of bone age. Thyroid hormone interacts with each of these pathways [1]. Introducing a TR-β agonist during this window could perturb the timing and tempo of these processes in ways that are not yet characterized.

Growth Plate and Bone Age Effects

Thyroid hormone accelerates chondrocyte differentiation and promotes epiphyseal fusion [2]. In children with untreated hyperthyroidism, advanced bone age and reduced adult height are well-documented outcomes [8]. Resmetirom's hepatic selectivity is partial, not absolute. In the MAESTRO-NASH trial, no bone mineral density or bone age endpoints were collected, so whether the 80 mg or 100 mg doses produce measurable skeletal effects even in adults remains unknown from trial data alone [6].

If resmetirom were used off-label in a 13-year-old with Tanner Stage 2 to 3 development, the growth plate is maximally active and potentially most sensitive to any thyromimetic signal. A bone age X-ray at baseline and every 6 months would be the minimum monitoring standard a clinician could defend.

Pubertal Hormone Axis

TR-β is expressed in the pituitary and hypothalamus and participates in the regulation of TSH secretion and, indirectly, LH and FSH pulsatility [1]. Exogenous TR-β agonism suppresses TSH via a negative feedback loop, as seen in MAESTRO-NASH where resmetirom produced dose-dependent TSH suppression in adult participants [6]. TSH suppression during puberty could theoretically alter gonadotropin pulsatility, though no clinical data in adolescents currently confirm or refute this.

Hepatic Maturation and Drug Metabolism

Adolescent hepatic CYP enzyme activity and drug-transporter expression differ from adults. CYP3A4, which is involved in resmetirom metabolism, reaches adult levels only in mid-to-late adolescence [9]. This means drug exposure (AUC) in a 12- or 14-year-old could differ substantially from the adult pharmacokinetic profile on which the 80 mg and 100 mg doses were based. Without pediatric PK data, dosing an adolescent with adult-labeled doses carries meaningful pharmacokinetic uncertainty.

Liver Disease in Adolescents: The Underlying Clinical Problem

Understanding why resmetirom might ever be considered for adolescents requires acknowledging that pediatric MASH is a real and undertreated disease. The TONIC trial (N=173 children, ages 8 to 17) established that neither vitamin E nor metformin significantly improved MASH histology compared to placebo at 96 weeks, leaving no approved pharmacological treatment for pediatric MASH as of 2025 [10]. That therapeutic vacuum creates pressure to consider agents like resmetirom before pediatric safety data exist.

Current Standard of Care for Adolescent MASH

The American Association for the Study of Liver Diseases (AASLD) 2023 guidance on MASLD recommends lifestyle intervention (diet, physical activity, weight management) as first-line treatment for pediatric patients, with no pharmacologic agent currently endorsed for routine use in the 12 to 17 age range [11]. Bariatric surgery data in adolescents (from the Teen-LABS cohort) show durable MASH resolution with sufficient weight loss, but surgery carries its own developmental considerations [12].

Why Clinicians May Still Ask About Resmetirom

A 16-year-old with biopsy-proven F3 MASH who has failed 18 months of intensive lifestyle therapy presents a genuine clinical dilemma. The AASLD guidance acknowledges that individual cases may warrant off-label pharmacologic consideration under specialist supervision [11]. In that context, understanding resmetirom's developmental risk profile becomes directly clinically relevant, even before any formal pediatric approval.

Metabolic and Lipid Effects: What Adult Data Suggest

Resmetirom lowers LDL-C, triglycerides, and hepatic fat fraction through TR-β-mediated upregulation of hepatic LDL receptors and fatty acid oxidation genes [13]. In MAESTRO-NASH, the 100 mg dose reduced LDL-C by approximately 16.3% and triglycerides by 22.6% vs. Placebo at 52 weeks [6]. These metabolic effects are potentially beneficial in an adolescent with obesity-driven dyslipidemia, but the long-term consequences of sustained TR-β agonism on lipid metabolism during the developmental period have not been studied.

Lipid Lowering in Context

Adolescent dyslipidemia management follows the 2018 American Heart Association/American College of Cardiology guideline, which emphasizes lifestyle therapy and, when necessary, statins [14]. Resmetirom is not positioned as a lipid-lowering agent for general use, and its liver-specific mechanism does not replace statin therapy in adolescents with familial hypercholesterolemia or severe dyslipidemia.

Gallbladder Effects

The FDA label for resmetirom includes a warning about cholelithiasis and cholecystitis; in MAESTRO-NASH, gallstone-related adverse events occurred in 12.9% of the 100 mg group vs. 7.5% placebo [5]. Pediatric gallstone disease is uncommon but not rare, particularly in obese adolescents. Adding a drug that nearly doubles gallstone risk to a population already at elevated baseline risk warrants careful individual risk-benefit analysis.

Safety Signals From the Adult Trial Relevant to Adolescents

Several MAESTRO-NASH safety findings deserve specific translation to the adolescent context.

TSH Suppression

Dose-dependent TSH suppression was observed: mean TSH fell from baseline in both dose groups, though values remained within the normal reference range for most participants [6]. In adolescents, even low-normal TSH levels have implications for bone turnover, growth velocity, and pubertal timing. A suppressed-but-normal TSH in a 14-year-old is not the same physiological state as in a 45-year-old.

Nausea and Gastrointestinal Tolerability

Nausea occurred in 25.2% of the 100 mg resmetirom group vs. 12.8% placebo in MAESTRO-NASH [6]. Adolescents, particularly those with concomitant eating concerns or who are already managing weight, may find GI intolerance more new. Nutritional adequacy during active growth phases is a distinct concern not captured by adult trial endpoints.

Liver Enzyme Elevations

Transient ALT and AST elevations occurred in a small percentage of MAESTRO-NASH participants [6]. In an adolescent with underlying MASH, distinguishing drug-induced hepatotoxicity from disease progression would require more frequent monitoring than standard adult protocols.

A Proposed Monitoring Framework if Resmetirom Is Used Off-Label in an Adolescent

No published guideline addresses resmetirom monitoring in adolescents specifically. Based on the adult safety profile [5,6], known TR-β biology in development [1,2,3], and pediatric endocrinology standards [8], a reasonable monitoring schedule for a 12 to 17-year-old receiving resmetirom off-label under specialist supervision might include the following parameters.

Baseline Assessments

Before starting resmetirom in any adolescent, clinicians should document: standing height and weight (with height velocity calculated if prior measurements are available), Tanner stage, bone age X-ray (left hand and wrist), fasting TSH and free T4, fasting lipid panel, ALT/AST/GGT, and a liver elastography or biopsy report confirming fibrosis stage.

Ongoing Monitoring Intervals

At 3-month intervals: TSH, free T4, ALT/AST, height and weight, symptom review for GI intolerance and musculoskeletal pain. At 6-month intervals: repeat bone age X-ray (if growth plates remain open), Tanner stage reassessment, fasting lipid panel, liver elastography. At 12 months: full hepatic histology reassessment if clinically indicated, endocrinology consultation if TSH has fallen below 0.5 mU/L on two consecutive measurements, or if height velocity has decelerated by more than 2 cm per year from pre-treatment trajectory.

This framework is not an FDA-approved or AASLD-endorsed protocol. It represents a synthesis of available developmental biology evidence and adult safety data pending formal pediatric trial results.

What Ongoing Research Could Change This Picture

The MAESTRO program includes longer-term extension studies in adults, and Madrigal Pharmaceuticals has indicated interest in studying resmetirom in pediatric populations [13]. A Phase 2 dose-finding trial in adolescents aged 12 to 17 would need to include PK sampling, bone age endpoints, pubertal staging, and TSH monitoring as primary or co-primary safety outcomes, not afterthoughts.

The NIH-funded NASH Clinical Research Network (CRN) has historically driven pediatric NAFLD/MASH trial infrastructure, including the TONIC trial [10]. Collaboration between Madrigal and the CRN represents the most likely path to a well-powered adolescent safety and efficacy study. Until that data exists, the FDA-mandated label indication remains adult-only, and the AASLD guidance supports no off-label use of resmetirom as standard care in patients under 18.

The 2024 AASLD Practice Guidance states: "Pharmacologic therapy for MASH should currently be reserved for patients with at-risk MASH (NAS score of 4 or more with at least 1 point each for steatosis, lobular inflammation, and ballooning, or fibrosis stage F2, F3), and no approved agent exists for pediatric patients" [11].

Separately, the FDA's 2024 prescribing information for resmetirom notes: "The safety and effectiveness of REZDIFFRA in pediatric patients have not been established" [5].